2026-04-18T02:40:11Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1870562025-12-05T11:57:28Zcom_2072_1057col_2072_478916col_2072_478917

Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients Rokx, Casper Lammers, Jolanda Buitenhuis, Lonneke Postma, Douwe Koster, David Lukens, Michaèl Scholtens, Thea Boomgaard, Maartje van den Kampschreur, Linda Ubals Cazorla, Maria Prat, Núria Soetekouw, Robert Vall Mayans, Martí Band, Caterina Carceles Peiró, Victor Gallardo, Mireia Casares Gonzalez, Pablo Galvan Femenia, Ivan Comas Leon, Xavier Millat Martínez, Pere Bassat Orellana, Quique Garcia, Nadia González, María Isabel Ancochea, Àgueda Grífols, Joan Ramon Verdaguer, Joaquim Roquer López, Clàudia Contreras, Enric Giménez, Montserrat Arcos Vila, Gemma Ouchi, Dan Blanco Guillermo, Ignacio Vértiz Guidotti, Thatiana Bonet Papell, Glòria Dastis Arias, Macarena Delgado Capel, Maria Briones Zambrano, Ney Nicanor Ferrer, Magí Videla, Sebastià Gudiol González, Carlota Fernández Rivas, Gema CoV-Early Study Group García, Yolanda Ruiz Comellas, Anna Vonderen, Marit van Bianco, Andrea Sofia Bravo, Anna Otero, Aurema Millan, Anna Ruibal Suarez, Jose Carlos Benavent, Sergio Zarauza Pellejero, Alvaro Línio, Rosa Malchair, Pierre Baro, Bàrbara Roca Font, Judit Carrasco Matos, Katherine M. Saüch Valmaña, Glòria Vidal Obradors, Carla Katsikis, Peter Capdevila Jáuregui, Mar Koopmans, Marion Ara, Jordi COnV-ert Study Group Rodríguez Codina, Joana Hernández, Luis Tarres García, Silvia Blanco, Ignacio Hernández, Águeda González Soler, Victoria Curriu Sabatès, Margarida Fornos, Miriam Casamitjana, Natàlia Bordoy, Antoni E. Alonso, Eva Groeneveld, Geert Reusken, Chantal Zwet, Erik van Miedema, Jelle Müller, Yvonne Martinez, Núria Ramírez Morros, Anna Bogers, Susanne Maglio, Laura Analía Amado Simon, Rosa Comellas Fernandez, Laura Viozquez Meya, Maria Costes, Gèlia Pradenas Saavedra, Edwards Forcada, Anna Gammeren, Adriaan van Ginneken, Betty van Harvala, Heli Zwaginga, Lisa Marfil, Silvia Troxel, Andrea Mooijaart, Simon Trinité, Benjamin San José, Alba Piccolo Ferreira, Francini Bonet, Mireia Blanco, Julian Cantoni, Jordi Russcher, Henk Marks, Michael Oud, Josine Zwaginga, Jaap Jan Torrano Soler, Pamela Mitjà Villar, Oriol Rijnders, Bart J. A. Droog, José de Ferrer, Susana Alemany Ortiz, Andrea Corbacho Monné, Marc Scherpenisse, Cees Hollander, Jan den Gharbharan, Arvind Meier, Romy Rokx, Casper Jordans, Carlijn Geurtsvankessel, Corine Albersen, Arjan Papageourgiou, Grigorios Puig, Jordi Engen, Rene van Karisli, Ayten Götz, Hannelore Struik, Jelle Díez Sánchez, Beatriz González Beiras, Camila París, Alexa Suñer Navarro, Clara Clotet, Bonaventura, 1953- Reimerink, Johan Maas, Nanda Rokx-Niemantsverdriet, Lotte Rodriguez Arias, Miquel Angel Jiménez, Zahida Verstijnen, Jose Geloven, Nan van Swaneveld, Francis Ramírez Viaplana, Ferran Schoot, Ellen van der Vrielink, Hans Llopis Roca, Ferran Gonzalez Ruiz, Cristian Flores Aguilera, Begoña Vivero Larraza, Ainhoa Pons Barber, Maria Watering, Leo van de Hogema, Boris González García, David Wijngaarden, Peter van Vidal Alaball, Josep Etten, Ronald van Berg – Rahman, Juliette van der Karim, Faiz Hiddema, Siepke Elst, Kim van Nieto Rodríguez, Raquel García García, Vanesa Casañ Lopez, Cristina Rodriguez Cortez, Orlando Leeuwen-Segarceanu, Elena van Nieto, Aroa Rodríguez Sevilla, Graciela Reitsma, Annette Navarrete Gonzalez, Laura Molenkamp, Karin COVID-19 Immunoregulació COVID-19 Immunoregulation Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when <20% of recruitment target was achieved. A Bayesian-adaptive individual patient data metaanalysis was implemented. Outpatients aged >= 50 years and symptomatic for <= 7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with <= 5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution. 2022-06-27T10:25:57Z 2022-06-27T10:25:57Z 2022-05-11 2022-06-23T11:35:25Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1038/s41467-022-29911-3 Nature Communications, 2022, vol. 13, num. 1 https://doi.org/10.1038/s41467-022-29911-3 cc by (c) Rokx, Casper et al, 2022 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess Springer Science Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))